Aggressive amelanotic melanoma in a patient with oculocutaneous albinism type 1a: a limited response to targeted and immune therapies

Clinical and Experimental Dermatology 2026

View at publisher
Authors: Yoko Amagata, Natsuko Saito‐Sasaki, Etsuko Okada, Yu Sawada
DOI: 10.1093/ced/llag042
Cited by: 0
References: 5

Abstract

We report an aggressive amelanotic melanoma in a patient with genetically confirmed oculocutaneous albinism type 1A. The tumour showed poor response to targeted and immune therapies. RNA sequencing analysis suggested a link between pigment loss and programmed death-ligand 1 upregulation.

Fields of Study & Subjects

Cutaneous Melanoma Detection and Management Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways

Publication details

Journal / source
Clinical and Experimental Dermatology
Volume
51
Issue
6
Pages
1107–1109
Publication date
24 January 2026
Language
EN